204 related articles for article (PubMed ID: 27823771)
1. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
Frumovitz M; Munsell MF; Burzawa JK; Byers LA; Ramalingam P; Brown J; Coleman RL
Gynecol Oncol; 2017 Jan; 144(1):46-50. PubMed ID: 27823771
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
[TBL] [Abstract][Full Text] [Related]
6. Improved survival with bevacizumab in advanced cervical cancer.
Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
Lee JY; Park JY; Park SY; Lee JW; Kim JW; Kim YB; Jeong DH; Lee KB; Kim TH; Lee IH; Choi MC; Kim KH; Kim YM; Lee YJ; Kang S; ; Pujade-Lauraine E
Gynecol Oncol; 2019 Jan; 152(1):61-67. PubMed ID: 30409490
[TBL] [Abstract][Full Text] [Related]
10. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
[TBL] [Abstract][Full Text] [Related]
11. Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.
Choi HJ; Lee YY; Choi CH; Kim TJ; Lee JW; Bae JH; Bae DS; Kim BG
Curr Probl Cancer; 2020 Oct; 44(5):100557. PubMed ID: 32067746
[TBL] [Abstract][Full Text] [Related]
12. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
[TBL] [Abstract][Full Text] [Related]
13. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
14. Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy.
Mahdi H; Rizzo A; Rose PG
Int J Gynecol Cancer; 2015 Mar; 25(3):467-73. PubMed ID: 25695549
[TBL] [Abstract][Full Text] [Related]
15. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
Paton F; Paulden M; Saramago P; Manca A; Misso K; Palmer S; Eastwood A
Health Technol Assess; 2010 May; 14 Suppl 1():55-62. PubMed ID: 20507804
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
Tinker AV; Fiorino L; O'Dwyer H; Kumar A
Int J Gynecol Cancer; 2018 Oct; 28(8):1592-1599. PubMed ID: 30247250
[TBL] [Abstract][Full Text] [Related]
17. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Tewari KS; Sill MW; Birrer MJ; Penson RT; Huang H; Moore DH; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
Gynecol Oncol; 2023 Apr; 171():141-150. PubMed ID: 36898292
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
Zighelboim I; Wright JD; Gao F; Case AS; Massad LS; Mutch DG; Powell MA; Thaker PH; Eisenhauer EL; Cohn DE; Valea FA; Alvarez Secord A; Lippmann LT; Dehdashti F; Rader JS
Gynecol Oncol; 2013 Jul; 130(1):64-8. PubMed ID: 23591400
[TBL] [Abstract][Full Text] [Related]
19. Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
Gass P; Thiel FC; Häberle L; Ackermann S; Theuser AK; Hummel N; Boehm S; Kimmig R; Reinthaller A; Becker S; Hilpert F; Janni W; Vergote I; Harter P; Emons J; Hein A; Beckmann MW; Fasching PA; Pöschke P;
Gynecol Oncol; 2024 Apr; 183():25-32. PubMed ID: 38490057
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
